Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07572097

High-Frequency Irreversible Electroporation vs Standard of Care for Benign Prostatic Hyperplasia

The study aims to find a better surgical treatment for men with an enlarged prostate (Benign Prostatic Hyperplasia, or BPH) that effectively relieves urinary symptoms without sacrificing sexual function.

Currently, standard surgeries like TURP or HoLEP are very effective at opening the blocked urinary channel. However, because they use heat or mechanical energy to remove prostate tissue, they often cause unwanted side effects, most notably the loss of normal ejaculation (retrograde ejaculation) and potential impacts on erectile function.

This study is testing a novel, minimally invasive technology called High-Frequency Irreversible Electroporation (H-FIRE). Instead of using heat to burn or cut the tissue, H-FIRE delivers ultra-short electrical pulses to destroy the blocking prostate tissue. This "non-thermal" (heat-free) approach is uniquely designed to spare the delicate nerves, blood vessels, and muscles surrounding the prostate, which are critical for preserving normal sexual function and bladder control.

In this clinical trial, 288 men aged 50 and older with moderate-to-severe BPH symptoms will be randomly assigned to receive either the investigational H-FIRE procedure or the Standard of Care surgery (TURP or HoLEP).

The main goal of the study is to prove that H-FIRE is just as effective as standard surgery in relieving lower urinary tract symptoms over 12 months. More importantly, the study will evaluate if H-FIRE is superior in helping patients achieve the "BPH Trifecta"-meaning the patient successfully achieves significant symptom relief, maintains perfect bladder control (uses zero pads), AND fully preserves normal ejaculation.

By utilizing this new tissue-sparing technology, the trial hopes to offer aging men a treatment option that restores their urinary health while fully protecting their overall quality of life.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

BPH

Age range

50 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Moderate-to-severe symptoms, defined as IPSS ≥13. Prostate volume (PV) between 30 and 150 ml, measured by multi-parametric MRI (mpMRI) or Transrectal Ultrasound (TRUS).

Maximum urinary flow rate (Qmax) ≤15 ml/s. Note: To ensure validity, the voided volume during uroflowmetry must be ≥125 ml; tests with lower volumes must be repeated.

Competency to provide informed consent and comply with long-term follow-up.

Exclusion criteria

Suspected or histologically confirmed prostate cancer. Patients with PSA >4 ng/ml must undergo mpMRI; those with PI-RADS ≥3 lesions require a negative biopsy before enrolment.

Neurogenic bladder, detrusor underactivity, or active urinary tract infection (UTI).

Previous prostate surgery, pelvic irradiation, urethral stricture, or bladder neck contracture.

Presence of metallic implants incompatible with H-FIRE pulse delivery (e.g., non-compatible pacemakers).

Inability to safely discontinue anticoagulation if required by the assigned surgical protocol.

Treatment and study plan

H-FIRE

Procedure

High-Frequency Irreversible Electroporation (H-FIRE) is a novel, non-thermal, tissue-selective ablation technique. Under transrectal ultrasound (TRUS) guidance, 19-gauge monopolar electrodes are inserted transperineally via a template to bracket the prostatic transition zone. The H-FIRE generator delivers ultrashort bursts of high-voltage microsecond-pulsed electric fields . This rapidly destabilizes the transmembrane potential, creating permanent nanoscale pores in the cell membrane and inducing cellular apoptosis rather than coagulative necrosis. This unique non-thermal mechanism is designed to effectively ablate obstructing prostatic adenoma while sparing the collagenous architecture of neurovascular bundles and the external sphincter.

Surgical Standard of Care (TURP or HoLEP)

Procedure

The Standard of Care (SoC) intervention comprises guideline-endorsed transurethral surgical procedures for benign prostatic obstruction. The specific surgical modality is strictly mandated by baseline prostate volume stratification to ensure optimal therapeutic efficacy. For prostates measuring 30 to 80 mL, surgeons perform either Transurethral Resection of the Prostate (TURP, Monopolar or Bipolar) or Holmium Laser Enucleation of the Prostate (HoLEP). For larger prostates (>80 to 150 mL), HoLEP is strictly mandated. Both procedures are performed under anesthesia with the clinical goal of achieving complete anatomical removal of the obstructing adenoma (resection to the surgical capsule for TURP, or anatomical enucleation for HoLEP).

Primary outcomes

  1. Change from Baseline in International Prostate Symptom Score (IPSS)

    Time frame: Baseline and 12 months

    The IPSS is a validated 7-item questionnaire assessing lower urinary tract symptoms. The total score ranges from 0 to 35. Higher scores indicate more severe symptoms (0-7: mildly symptomatic; 8-19: moderately symptomatic; 20-35: severely symptomatic). A decrease in the score indicates symptomatic improvement.

Secondary outcomes

  1. Proportion of Participants Achieving the "BPH Trifecta"

    Time frame: 1,3,6,12 months

    The "BPH Trifecta" is a composite success endpoint defined as the simultaneous achievement of three criteria: (i) Effective de-obstruction (IPSS reduction >=50% from baseline or total score <8); (ii) Social Continence (0 pads/day); and (iii) Preservation of Ejaculation (MSHQ-EjD Function Score >=2).

  2. Change from Baseline in International Index of Erectile Function (IIEF-5) Score

    Time frame: Baseline, 1, 3, 6, and 12 months

    The IIEF-5 is a validated questionnaire assessing erectile dysfunction. Total scores range from 1 to 25. Higher scores indicate better erectile function and lesser severity of dysfunction.

  3. Change from Baseline in Male Sexual Health Questionnaire for Ejaculatory Dysfunction (MSHQ-EjD) Short Form Score

    Time frame: Baseline, 1, 3, 6, and 12 months

    The MSHQ-EjD Short Form assesses ejaculatory function. The function domain score ranges from 1 to 15. Higher scores indicate better ejaculatory function (greater frequency, strength, and volume).

  4. Change from Baseline in Maximum Urinary Flow Rate (Qmax)

    Time frame: Baseline, 1, 3, 6, and 12 months

    Maximum urinary flow rate (Qmax) evaluated via uroflowmetry. Assessed with a minimum voided volume requirement of 125 mL. Higher values indicate better urinary flow and less obstruction.

  5. Change from Baseline in Post-Void Residual (PVR) Urine Volume

    Time frame: Baseline, 1, 3, 6, and 12 months

    Post-void residual (PVR) urine volume measured via transabdominal ultrasound immediately after a voluntary void. Lower values indicate better bladder emptying.

  6. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Up to 12 months post-procedure

    Adverse events will be systematically recorded and graded. Surgical complications will be classified using the Clavien-Dindo Classification system. General medical adverse events and genitourinary symptoms will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Key Adverse Events of Special Interest (AESI) include urethral stricture, transient/permanent incontinence, and retrograde ejaculation.

  7. Incremental Cost-Effectiveness Ratio (ICER)

    Time frame: 12 months

    The ICER will be calculated from a societal perspective as the incremental cost per Quality-Adjusted Life Year (QALY) gained. QALYs will be derived from the EQ-5D-5L utility index scores. Lower ICER values indicate a more cost-effective intervention.

Study contacts

Contact information is provided by the study sponsor or research team.

Shanghai East hospital ethics committee

CONTACT

[email protected]

+86-021-38804518

Sponsors and collaborators

Lead sponsor

Shanghai East Hospital

Other

Registry information

Official study title

High-Frequency Irreversible Electroporation vs Standard of Care for Benign Prostatic Hyperplasia: Adaptive Platform Study

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
May 7, 2026
Registry last updated
May 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.